Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;19(6):1585-1588.
doi: 10.1111/jth.15341. Epub 2021 May 20.

Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology

Ishac Nazy  1   2 , Ulrich J Sachs  3 , Donald M Arnold  1   2 , Steven E McKenzie  4 , Phil Choi  5   6 , Karina Althaus  7   8 , Maria Therese Ahlen  9 , Ruchika Sharma  10 , Rachael F Grace  11 , Tamam Bakchoul  12
Affiliations

Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology

Ishac Nazy et al. J Thromb Haemost. 2021 Jun.

Abstract

Vaccine administration is under way worldwide to combat the current COVID-19 pandemic. The newly developed vaccines are highly effective with minimal adverse effects. Recently, the AstraZeneca ChadOx1 nCov-19 vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine-induced immune thrombotic thrombocytopenia (VITT). These thrombotic events appear similar to heparin-induced thrombocytopenia, both clinically and pathologically. In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT.

Keywords: AstraZeneca ChadOx1 nCov-19 vaccine; COVID-19; platelet activation; thrombocytopenia; thrombosis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Recommendations for laboratory diagnosis and patient management following bleeding and/or thrombosis after vaccination with the AstraZeneca Vaccine for COVID‐19
See this image and copyright information in PMC

References

    1. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical characteristics of coronavirus disease in China. N Engl J Med. 2019;2020(382):1708–1720. - PMC - PubMed
    1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
    1. Helms J., Tacquard C., Severac F., et al. High risk of thrombosis in patients with severe SARS‐CoV‐2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–1098. - PMC - PubMed
    1. Klok F.A., Kruip M., van der Meer N.J.M., et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID‐19: an updated analysis. Thromb Res. 2020;191:148–150. - PMC - PubMed
    1. Nahum J., Morichau‐Beauchant T., Daviaud F., et al. Venous thrombosis among critically Ill patients with coronavirus disease 2019 (COVID‐19) JAMA Netw Open. 2020;3 - PMC - PubMed